Heranba Industries Ltd
Incorporated in 1994, Heranba Industries Ltd is engaged in the manufacturing of a diverse range of agrochemicals such as insecticides, herbicides, fungicides and public health products for pest control. [1]
- Market Cap ₹ 1,146 Cr.
- Current Price ₹ 286
- High / Low ₹ 426 / 268
- Stock P/E 17.0
- Book Value ₹ 211
- Dividend Yield 0.43 %
- ROCE 17.7 %
- ROE 14.3 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 25.0%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|
514 | 582 | 741 | 1,004 | 951 | 1,219 | 1,450 | 1,324 | 1,272 | |
470 | 534 | 653 | 873 | 822 | 997 | 1,190 | 1,163 | 1,173 | |
Operating Profit | 44 | 48 | 88 | 131 | 129 | 221 | 260 | 161 | 100 |
OPM % | 9% | 8% | 12% | 13% | 14% | 18% | 18% | 12% | 8% |
1 | 2 | 5 | 7 | 17 | 7 | 19 | 14 | 24 | |
Interest | 13 | 12 | 12 | 11 | 9 | 5 | 4 | 8 | 10 |
Depreciation | 4 | 4 | 5 | 6 | 8 | 15 | 20 | 23 | 24 |
Profit before tax | 28 | 35 | 76 | 122 | 129 | 208 | 255 | 144 | 90 |
Tax % | 39% | 41% | 39% | 38% | 24% | 26% | 26% | 24% | |
17 | 20 | 47 | 75 | 98 | 154 | 189 | 110 | 68 | |
EPS in Rs | 21.61 | 26.01 | 60.02 | 19.31 | 25.00 | 38.54 | 47.25 | 27.52 | 16.88 |
Dividend Payout % | 13% | 10% | 9% | 5% | 6% | 4% | 4% | 5% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 12% |
3 Years: | 12% |
TTM: | -10% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 19% |
3 Years: | 4% |
TTM: | -51% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -23% |
1 Year: | 9% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 27% |
3 Years: | 25% |
Last Year: | 14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 39 | 39 | 40 | 40 | 40 | 40 |
Reserves | 91 | 108 | 150 | 189 | 282 | 488 | 674 | 776 | 805 |
96 | 84 | 76 | 50 | 43 | 52 | 91 | 93 | 88 | |
130 | 120 | 217 | 282 | 261 | 263 | 302 | 250 | 443 | |
Total Liabilities | 325 | 321 | 450 | 560 | 625 | 843 | 1,108 | 1,159 | 1,376 |
37 | 38 | 46 | 51 | 95 | 133 | 193 | 186 | 196 | |
CWIP | 0 | 0 | 1 | 16 | 38 | 10 | 14 | 42 | 55 |
Investments | 0 | 0 | 0 | 0 | 4 | 10 | 2 | 1 | 1 |
287 | 282 | 403 | 493 | 488 | 690 | 898 | 930 | 1,125 | |
Total Assets | 325 | 321 | 450 | 560 | 625 | 843 | 1,108 | 1,159 | 1,376 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|
52 | 54 | 60 | 98 | 122 | ||||
-25 | -52 | -41 | -82 | -100 | ||||
-26 | -20 | 62 | -6 | -18 | ||||
Net Cash Flow | 1 | -18 | 82 | 10 | 4 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|
Debtor Days | 102 | 78 | 100 | 92 | 99 | 102 | 112 | 107 |
Inventory Days | 76 | 86 | 68 | 60 | 83 | 78 | 100 | 122 |
Days Payable | 96 | 84 | 129 | 123 | 122 | 92 | 96 | 77 |
Cash Conversion Cycle | 83 | 79 | 39 | 29 | 61 | 89 | 116 | 152 |
Working Capital Days | 98 | 89 | 76 | 58 | 83 | 96 | 116 | 131 |
ROCE % | 24% | 41% | 52% | 43% | 45% | 37% | 18% |
Documents
Announcements
- Closure of Trading Window 1d
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
10 Feb - Result for Quarter ended on the December 31, 2023 has been published in the Newspaper, the details of which are given in the Letter attached …
- Q3FY24 Result 9 Feb
- Board Meeting Outcome for Outcome Of Board Meeting 9 Feb
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 9 Feb
Annual reports
Concalls
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Jan 2022TranscriptNotesPPT
-
Dec 2021TranscriptPPT
-
Nov 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Aug 2021TranscriptNotesPPT
-
Jun 2021Transcript PPT
Product Portfolio
The Co.’s portfolio comprises intermediates, technicals and formulations.
Intermediates: Intermediates manufactured are for Co.’s own captive consumption for manufacturing various Technicals and Formulations. [1] These include CMAC, Bromobenzenes, Metaphenoxy, etc.
Technicals: These include Cypermethrin, Deltamethrin, Alpha Cypermethrin, Acephate, Lambda Cyhalothrin, etc.
Formulations: Formulations and branding of formulations are a forward integration to Heranba’s technical business. These include Emulsifiable Concentrate (EC), Water Dispersible Granule (WDG), Suspension concentrate, Capsule Suspension (CS), etc.
It has 400 product registrations in 49 countries,210 registrations in pipeline in 49 countries. 24 Technicals,193 formulations are registered for manufacture & sale in India.68 technicals & 65 formulations are registered for manufacture and sale in export markets
{#https://www.bseindia.com/bseplus/AnnualReport/543266/73414543266_05_07_22.pdf#page=4 #}